Xilio Therapeutics (XLO) Competitors

Nabriva Therapeutics (NASDAQ:NBRV) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, community ranking, profitability, analyst recommendations, earnings and dividends.

Does the media prefer NBRV or XLO?

In the previous week, Nabriva Therapeutics and Nabriva Therapeutics both had 2 articles in the media. Nabriva Therapeutics' average media sentiment score of 1.18 beat Xilio Therapeutics' score of 0.00 indicating that Xilio Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nabriva Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xilio Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, NBRV or XLO?

Nabriva Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the S&P 500.

Which has stronger earnings & valuation, NBRV or XLO?

Nabriva Therapeutics has higher revenue and earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A
Xilio Therapeutics	N/A	N/A	-$76.40M	-$2.78	-0.45

Do institutionals and insiders hold more shares of NBRV or XLO?

0.3% of Nabriva Therapeutics shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 1.6% of Nabriva Therapeutics shares are held by company insiders. Comparatively, 4.6% of Xilio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Does the MarketBeat Community prefer NBRV or XLO?

Nabriva Therapeutics received 382 more outperform votes than Xilio Therapeutics when rated by MarketBeat users. However, 73.33% of users gave Xilio Therapeutics an outperform vote while only 58.57% of users gave Nabriva Therapeutics an outperform vote.

Company	Underperform	Outperform
Nabriva Therapeutics	Outperform Votes 393 58.57%	Underperform Votes 278 41.43%
Xilio Therapeutics	Outperform Votes 11 73.33%	Underperform Votes 4 26.67%

Do analysts rate NBRV or XLO?

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nabriva Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Xilio Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is NBRV or XLO more profitable?

Xilio Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -148.11%. Nabriva Therapeutics' return on equity of -126.55% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%
Xilio Therapeutics	N/A	-126.55%	-89.20%

Summary

Xilio Therapeutics beats Nabriva Therapeutics on 9 of the 14 factors compared between the two stocks.